AOD-9604 in Plouisy — Fat Loss Peptide Research Guide
AOD-9604 research guide for Plouisy. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 won't be found on pharmacy shelves in Plouisy or anywhere else for that matter — it's a research-grade peptide supplied via a dedicated online market. What this means for Plouisy researchers is that geography is secondary to your ability to evaluate vendor quality — and those verification methods are available to every researcher. A properly operating AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide gives Plouisy researchers the framework to evaluate AOD-9604 vendors systematically and source verified-quality AOD-9604 with confidence.
How AOD-9604 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Plouisy comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Before looking at individual vendors, establish a quality benchmark — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA establishes that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. The combination of community consensus and independent COA review is the gold standard for AOD-9604 sourcing — community feedback surfaces patterns individual COA review misses, and vice versa. Hold lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Plouisy
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with sterile bacteriostatic water. Quality AOD-9604 sourcing is not separable from research safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. Protocol documentation — recording exactly what was used, when, and how — is a fundamental research principle that makes anomalous results interpretable.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.